P10 Working with the Pharmaceutical Industry
|
|
- Laureen Park
- 5 years ago
- Views:
Transcription
1 Working with the Pharmaceutical Industry Policy: P10 Policy Descriptor This document is intended to serve as a guide to Devon Partnership NHS Trust staff and the Trust as a whole with regard to interacting and working with the pharmaceutical industry. Related policies or documents: Code of Practice for the Pharmaceutical Industry 2016 The Bribery Act 2010 The Code of Conduct: Code of Accountability in the NHS Department of Health 2004 Do you need this document in a different format? Contact PALS or dpn-tr.pals@nhs.net Document Control Policy Ref No & Title: P10 Working with the Pharmaceutical Industry Version: 1.0 (Amn. Sept17 Sec 14.3) Replaces / dated: New Policy Author(s) Names / Job Title responsible / Ratifying committee: Director / Sponsor: Primary Readers: Additional Readers Date ratified: 19 th January 2017 Date issued: January 2017 Date for review: January 2019 Date archived: James Lee, Senior Clinical Pharmacist, jameslee5@nhs.net Tina Campbell, Chief Pharmacist, tinacampbell@nhs.net Medicines Optimisation Governance Group Dr Helen Smith Medical Director This policy is applicable to all Trust sites and applies to all Trust staff including independent contractors, agency and Bank staff. This policy may be made available to pharmaceutical representatives on request.
2 Contents 1. Introduction Purpose Definitions Duties Code of Conduct Philosophy underpinning the relationship between the Trust and the pharmaceutical industry General Information Promotional Activity Samples Hospitality & Meetings Sponsorship Appropriate Projects Principles of Collaborative Working Promotion of Sponsors Register of Sponsorship, Gifts & Hospitality Research & Development Clinical Trials Code of Ethics Monitoring References Acknowledgements These are the key points for action from this policy: Pharmaceutical representatives can be a useful resource for healthcare professionals and joint working with pharmaceutical industry can help create innovative new services to benefit patients. Staff must ensure that they act honestly and professionally when dealing with the pharmaceutical industry. Requests for sponsorship or running of joint events must first be approved by the local Area Lead Pharmacist by ing dpn-tr.pharmacyteam@nhs.net. A log of applications will be kept by the Medicines Optimisation team and reviewed as part of the Medicines Optimisation Governance Group. Sponsorship and gifts MUST also be declared according to the annual declaration process. 2
3 1. Introduction 1.1. The Trust understands the role which the pharmaceutical industry has to play in aiding health professionals in the provision of treatments that are safe and cost-effective for patients in their care Pharmaceutical representatives can be a useful resource for healthcare professionals and joint working with pharmaceutical industry can help create innovative new services to benefit patients This policy provides a framework to assist Trust staff in determining when commercial sponsorship from the pharmaceutical industry or a joint working agreement is appropriate whilst maintaining an impartial and honest approach to putting patients interests first Guidance on The ABPI Code of Practice for the Pharmaceutical Industry 2016 has been referred to in the creation of this document Disclaimer: It is not the intention of this policy to provide detailed considerations of all the possible circumstances or scenarios that may apply in terms of the Trust s interactions with pharmaceutical representatives. 2. Purpose 2.1. This policy aims to: set out the principles and standards which should be applied when Trust staff engage with pharmaceutical industry provide a guidance framework when developing joint working initiatives with pharmaceutical companies support corporate governance strategies within the Trust provide consistency across the Trust when dealing with the pharmaceutical industry. 3. Definitions 3.1. Commercial sponsorship is defined as including: NHS funding from an external source, e.g. funding of all or part of the costs of a member of staff, NHS research, staff training, pharmaceuticals, equipment, meeting rooms, costs associated with meetings, meals, gifts, hospitality, hotel and transport costs (including trips abroad), provision of free services (speakers), buildings or premises Hospitality is defined as the receipt of entertainment, gifts or cash (or equivalent) for personal use or benefit which has no direct benefit to patient care or the business of BEHMHT Joint working describes situations where, for the benefit of patients, NHS and industry organisations pool skills, experience and/or resources for the joint development and implementation of patient centred projects and share a commitment to successful delivery Duties 4.1. The Chief Executive is responsible for ensuring the Trust employs a comprehensive strategy to support the management of risk, including clinical risks associated with a person s mental ill health. 3
4 4.2. The Executive Directors are responsible for ensuring the Trust has robust policies and procedures for the management of clinical risk. They are also responsible for the strategic and operational delivery of a high quality of service provision and ensure that learning is applied following any adverse incidents Service Line Directors, Assistant Directors and Services Managers: are responsible for ensuring that all staff within their service lines receive regular supervision, are properly supported and receive their mandatory training The Trust s Chief Pharmacist has the overall responsibility for the establishment, maintenance and monitoring of the system for medicines optimisation and management across the Trust. This is in consultation with appropriate senior medical and nursing staff, and other relevant healthcare professionals The Ward / Service Manager: Is ultimately accountable for ensuring adequate systems are in place to control all the medicines in his/her ward or unit and that these systems are followed at all times. They are also responsible for ensuring that staff have access to this policy and have working knowledge of its contents 4.6. All staff are responsible for ensuring they are familiar with the contents of this policy and adhere to it. Any staff involved in organising hospitality meetings, seeking sponsorship or who are involved in any other form of collaborative working with the pharmaceutical industry are responsible for ensuring they are familiar with the contents of this policy and adhere to it. 5. Code of Conduct 5.1. Trust staff All staff including independent contractors, locums, agency and Bank staff are expected to: act impartially in all their work declare and record financial or personal interests (e.g. company shares, research grant/s) in any organisation with which they have to deal, and be prepared to withdraw from those dealings if required, thereby avoiding any conflict of interest not misuse their official position, or information acquired in the course of their official duties, to further their private interests beware of bias generated through sponsorship, where this might impinge on professional judgement and impartiality neither agree to practise under any conditions which may compromise professional independence or judgement, nor impose such conditions on other professionals or colleagues have a clear agenda from a pharmaceutical industry representative before agreeing to a meeting, which should be by appointment for a specified time and duration If other personnel arrive for the meeting other than those agreed in advance, then staff are at liberty to decide the optimal numbers for the meeting and should use their discretion as to whether it is appropriate to see the additional personnel. 4
5 Further meetings should not be arranged if the representative was unhelpful or unethical in any respect or if the meeting did not produce expected outcomes, such as relevant information on a new drug If a member of staff feels uncomfortable with an approach or offer from a company, then they should discuss it with their line manager in the first instance. Advice should then be sought from an appropriate service manager or the medicines optimisation team A record of the visit should be made Any behaviour by pharmaceutical industry personnel felt to be inappropriate should be reported to the medicines optimisation team and, in the first instance, this will be taken up with the representative s line manager. If no satisfactory outcome is achieved, then a complaint will be made to the Association of British Pharmaceutical Industries (ABPI) Pharmaceutical Representatives visiting Trust premises Visits to all Devon Partnership Trust sites should be made only to keep an agreed appointment, or to make such an appointment. Representatives are not allowed to tour Trust sites looking for staff, and are not to enter clinical areas without prior appointment with a senior member of staff. Only senior members of staff e.g. Consultants, SPRs (ST 4-6) and associate medical specialists, Lead nurses, ward managers, and Pharmacy Leads should see pharmaceutical representatives and this should be by a pre-arranged appointment. Junior staff are not authorised to see pharmaceutical representatives, or to provide them with information. Representatives MUST NOT visit or interview staff in clinical areas or other departments unless otherwise specifically invited to do so by the departmental manager. Representatives MUST NOT interview patients. Representatives arriving for a pre-arranged appointment MUST have photographic identification, which clearly states his/her name, company and position. 6. Philosophy underpinning the relationship between the Trust and the pharmaceutical industry 6.1. The Trust acknowledges the inter-dependent relationship between the pharmaceutical industry and the NHS The Trust believes there is a clear demarcation between the research and healthcare development interests and the marketing operations of the companies involved. However, promotion of products to mental health practitioners should be based on reputable peerreviewed evidence / practice The Trust does not support the issuing of samples, as treatment choice should be determined by rational (efficacy, safety and cost) prescribing / or treatment decisions The Trust has a duty to explore and develop the relationship between itself and the pharmaceutical industry for the benefit of the patients and clients of the Trust within a clear 5
6 ethical framework and the NHS s need to ensure evidence based decision-making, value for money and equity. 7. General Information 7.1. Pharmaceutical representatives should respect their position as visitors to the Trust, and recognise that the interests and priorities of the Trust may be different from their own The Trust will extend co-operation to drug companies where this is in the direct interest of patient care, and the general aims of the Trust It is recognised that in addition to providing information to health practitioners, the prime function of representatives is to promote and encourage the use of their company s products. It is expected that this task will be carried out in a proper manner in accordance with ABPI Code of Practice 2016, and that current NHS Policies will be observed The decision to agree the formulary inclusion of any product is to be made by the Trust s Drugs and Therapeutics Committee. 8. Promotional Activity 8.1. Representatives should inform the ward/service manager and Area Lead Pharmacist (by ing dpn-tr.pharmacyteam@nhs.net) in advance of any teaching or promotional activity which is to be undertaken on a ward or department. Approval must be gained first. Any comparisons made with existing Trust policies, drugs or practices in use in the Trust should be based on the results of properly controlled published studies The intent of the meeting must not contravene existing Trust policies or guidelines Pharmaceutical representatives should be well informed about the products that they are promoting. In addition to standard technical and clinical data, including information on comparative efficacy, the staff may wish to know what is being promoted, the basis for the promotion, and the specific place that the product is expected to have in therapy Price comparisons should not be used unless a senior pharmacist (Lead Pharmacist or above) has approved them in advance Misrepresentation of Trust information e.g. policies or clinical guidelines, within or outside the Trust will be construed as a deliberate attempt to contravene the Trust policy/ guideline. 9. Samples 9.1. Ordinarily samples for use in the hospital MUST NOT be left with medical staff or on wards or in departments 9.2. However in circumstances samples of products e.g. pharmaceuticals, dressings, devices or nutritional products may only be provided in order to assess their physical properties. They should not be used to treat patients Note: According to the ABPI Code of Practice, samples of a product can only be provided to a health professional in response to a written request, which has been signed and dated. 10. Hospitality & Meetings Pharmaceutical company sponsorship is permitted for academic meetings. It is not allowed for teaching sessions for junior doctors unless prior approval by the relevant consultant, senior registrar or associate specialist has been obtained. 6
7 10.2. Requests for running of events must first be approved by the local Area Lead Pharmacist by ing Pharmaceutical companies may sponsor departmental meetings, with the agreement of the departmental head and providing a senior member of staff attends the meeting Any hospitality MUST be secondary and appropriate to the purpose of the meeting and not out of proportion to the occasion If a meeting is sponsored by a pharmaceutical company or companies, this fact must be disclosed in all of the papers relating to the meetings and in any published proceedings. The declaration of sponsorship must be sufficiently prominent to ensure that readers are aware of it at the outset. 11. Sponsorship When developing a project that may include seeking sponsorship, staff should consider the following issues in the project planning stage: Commercial involvement with the NHS may be of mutual advantage, but both partners should assess and understand the costs and benefits of any such agreement Purchasing decisions should always be taken on the basis of best clinical practice and value for money, and should take into account their impact on other parts of the health care system (e.g. products dispensed in hospital which are likely to be required by patients regularly at home) Purchasing decisions on products that originate from NHS intellectual property must be based on best clinical practice and not on whether royalties will accrue to an NHS body Deals whereby sponsorship is linked to the purchase of particular product, or to supply from particular source, are not allowed, unless as a result of a transparent tender for a defined package of goods and services The confidentiality of patient information MUST be maintained. Where a sponsorship arrangement permitting access to patient information appears to be legally and ethically sound (e.g. where patients have explicitly consented), a contract should be drawn up which draws attention to obligations of confidentiality. This contract should specify the security standards that should be applied; limit the use of information to purposes specified in the contract; and make it clear that the contract will be terminated if the conditions are not met Where the major incentive to enter into a sponsorship arrangement is the generation of income the scheme must not interfere with the duties or obligations of the Trust Where more than one company produces products in a particular field, all (or a number) of companies must be offered the opportunity for sponsorship so as to ensure that the Trust does not favour one particular company As a general rule, sponsorship arrangements should be at a corporate level, rather than at a team, directorate, clinical service or individual level Sponsorship and the sponsoring company should never be in conflict with good health practices A written contract must be agreed between the Trust and the relevant company. The Trust Lead and the appropriate contact for the pharmaceutical company should sign the contract. 7
8 Requests for sponsorship must be approved by the local Area Lead Pharmacist by ing 12. Appropriate Projects The Trust will not accept sponsorship from the pharmaceutical industry to support initiatives that are not in line with its strategic priorities Any guidelines or protocols will be developed jointly with all appropriate person(s) employed within the Trust Joint initiatives between the Trust and the pharmaceutical industry must promote evidencebased practice and support only those initiatives that have been considered by the relevant Trust committees Sponsorship will not be accepted for projects that have the prime objective of increasing the usage of a specific brand of pharmaceutical or other product Any learning or products developed through sponsored projects may be shared with other NHS organisations. The Trust will retain the right of approval of associated literature and material. 13. Principles of Collaborative Working The following principles will also apply to collaborative working. All collaborative working projects should be conducted through an open and transparent process. Staff should be aware of NHS guidance, the legal position and appropriate and relevant professional codes of conduct as described in extant NHS guidance. Contract negotiations will be negotiated in line with NHS values. Confidentiality of information received in the course of duty must be respected and never used outside the scope of the specific project. Collaborative working arrangements should take place at a corporate, rather than an individual, level. Clinical and financial outcomes and risks or governance issues must be formally assessed at the planning stage by the Trust before the collaborative work commences. Projects should address local priorities and preferred service balance. All collaborative projects will maintain the freedom of all clinicians to prescribe the most clinically appropriate and effective treatment for individual patients in line with locally approved guidelines and formulary. Clinical and prescribing policies or guidelines will always be based upon principles of evidence based medicine and cost effectiveness. These will be consistent with National recommendations and expert bodies specifically the National Institute for Health and Care Excellence (NICE). A whole-systems approach will be taken to developing collaborations. This will ensure that only arrangements that benefit the whole NHS are approved. Those that lead to higher costs or a reduction in quality in other areas of the NHS, or shift the balance of 8
9 investment in service in a manner not consistent with local priorities, are not acceptable. Collaborative projects that focus on broader areas are to be preferred to those which focus on specific drugs or products. Projects that encourage the preferential prescribing of one product may be viewed as a financial incentive to prescribe and may contravene national guidance. Where products are deemed equally clinically effective, assessment of costeffectiveness may include the package of additional resources and support for each product The Department of Health and the ABPI have jointly produced a toolkit to support joint working this is available at: Promotion of Sponsors The logo of the sponsoring company MUST NOT appear on the front of leaflets or similar publications. The logo may appear on the back of the publication The sponsoring company s logo MUST NOT be more dominant than that of the Trust The use of sponsorship must not interfere or affect the normal activity of the Trust or the normal duties of staff. Promotional material of any medication or pharmaceutical company must not be on display in public areas or places where they may be viewable by patients or carers. Promotional material is discouraged from being available overtly in staff areas. 15. Register of Sponsorship, Gifts & Hospitality Members of NHS staff and independent contractors should record/ declare gifts, benefits and commercial sponsorship. A log of all requested will be kept by the Medicines Optimisation team and reviewed as part of the Medicines Optimisation Governance Group. Staff must also declare any sponsorship through the annual declaration process set out here The following do not need to be declared: Stationary e.g. pens and diaries and other low value promotional aids that are relevant to the recipients work. A low value promotional item is one that has cost the donor company no more than 6, excluding VAT. (This is the sum quoted in The ABPI Code of practice 2012, however for Trust purposes any hospitality above 25 must be declared). Income generation schemes, which will be logged separately at Trust level. Attendance at meetings held on Trust premises. 16. Research & Development While any research MUST have prior Ethical Committee approval before commencement, it is prudent to consider the following. Exceptionally, in the case of non-commercial research and development originated or hosted by NHS providers, commercial sponsorship may be linked to the purchase of particular products, or to supply from particular sources. This should be in accordance 9
10 with the guidance at paragraph 28 of HSG (97) 32 Responsibilities for meeting Patient Care Costs Associated with Research and Development in the NHS. Where there is industry collaboration in such studies, companies may alternatively make a contribution towards the study s costs, rather than supply a product. Any funding for research purposes should be transparent. There should be no incentive to prescribe more of any particular treatment or product other than in accordance with the peer reviewed and mutually agreed protocol for the specific research intended. When considering a research proposal, whether funded in whole or part by industry, NHS bodies will wish to consider how the continuing costs of any pharmaceutical or other treatment initiated during the research will be managed once the study ended. Where research is primarily for commercial purposes, NHS providers are expected to recover the full cost from the commercial company on whose behalf it is carried out. (HSC (96) 32, paragraph 7). An industry-sponsored trial should not commence unless an indemnity agreement is in place; see guidelines in HSC (96) 48 NHS Indemnity, Arrangements for Clinical Negligence Claims in the NHS. A standard form of indemnity agreement, agreed with ABPI, can be found at Annex B of that guidance. The NHS should benefit from commercial exploitation of intellectual property derived from research and development that the NHS had funded, or for which it has been funded, even where the intellectual property itself is owned by people outside the NHS. NHS bodies should ensure that an agreement to this effect is included in any contracts concerning research and development. The guidelines in HSC 1998/106 Policy Framework for the Management of Intellectual Property within the NHS from R&D should be followed. 17. Clinical Trials All clinical trials undertaken within the Trust MUST have prior Ethical Committee approval. Pharmaceutical companies planning to undertake clinical trials within this Trust must contact the relevant medical staff and provide such information as is required by the Ethical Committee in order for the committee to grant its approval for the trial to commence Contact should also be made with a senior pharmacist or the clinical trials pharmacist as early as possible before the trial commences, if appropriate Pharmacy will require a copy of the trial protocol and will fulfil its responsibilities to provide appropriate support to the trial, to protect patient safety and ensure compliance with all statutory requirements. 18. Code of Ethics Suppliers must not attempt to influence business decision-making by offering hospitality to Trust staff. The frequency and the scale of any hospitality accepted will be managed openly and with care by the Trust Commercial sponsorship relating to conferences or courses is only acceptable if the attendance of the Trust s staff forms a part on an education/training course approved by an accountable manager of the Trust Product trials must be arranged through the Research and Development department to ensure that: Trials are carried out on a controlled basis. The product in question meets the appropriate safety standards. 10
11 Trials are not duplicated Points that will be considered when product trials are being carried out are as follows: How the trial is to be administered How the trial is to be financed How trial pharmaceuticals is to be provided How long the trial will last Whether technical staff need to be involved Current safety regulations and quality standards How the trial will be assessed Whether the suppliers need to be involved The implications for existing contracts or purchasing agreements How the results of the trial will be disseminated 19. Monitoring Devon Partnership NHS Trust will ensure that regular monitoring of all policies takes place, this is overseen by the Trusts Policy Officer in partnership with relevant directorate and corporate clinical governance groups e.g. Directorate Governance Boards and Senior Management Board (Quality and Safety) to ensure compliance and maintain quality standards as in keeping with safe Clinical Practice. 20. References HR12 Standards of business conduct conflict of interest. Devon Partnership NHS Trust The ABPI Code of Practice for the Pharmaceutical Industry HSG (97)32: Responsibilities for meeting patient care costs associated with research and development in the NHS: The Department of Health - Pubs and stats: Letters and circulars HealthServiceGuidelinesArticle/fs/en?CONTENT_ID= &chk=ZUXc1q HSG (96)48: NHS indemnity arrangements for handling clinical negligence claims against NHS staff: The Department of Health - Pubs and stats: Letters and circulars HealthServiceGuidelinesArticle/fs/en?CONTENT_ID= &chk=0Hc10u HSC 1998/106: Policy framework for the management of intellectual property within the NHS arising from research & development : The Department of Health - Pubs and stats: Letters and circulars althservicecircularsarticle/fs/en?content_id= &chk=f Acknowledgements Acknowledgement to Barnet, Enfield and Haringey Mental Health Trust for their help in writing this policy. 11
Policy for the Sponsorship of Activities and Joint Working with the Pharmaceutical Industry
Policy for the Sponsorship of Activities and Joint Working with the Pharmaceutical Industry March 2017 NOTE: This policy will be subject to review in 2017/18 as part of the partnership work between North
More informationGuidance For Health Care Staff Within NHS Grampian On Working With The Pharmaceutical Industry And Suppliers Of Prescribable Health Care Products
Title: Identifier: Guidance For Health Care Staff Within NHS Grampian On Working With The Pharmaceutical Industry And Suppliers Of Prescribable Health Care Products NHSG/guid/PharmInd/GMMG/738 Replaces:
More informationSPONSORSHIP AND JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY
SPONSORSHIP AND JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY 1 SUMMARY This document sets out Haringey Clinical Commissioning Group policy and advice to employees on sponsorship and joint working with
More informationPolicy on Sponsorship and Joint Working with the Pharmaceutical Industry and other Commercial Organisations
Policy on Sponsorship and Joint Working with the Pharmaceutical Industry and other Commercial Organisations Author: Melanie Preston, Assistant Director of Medicines Optimisation Blackpool CCG & Louise
More informationVersion Number Date Issued Review Date V1 July /08/2015 July 2017
Corporate CCG CO23 Commercial Sponsorship and Joint Working with the Pharmaceutical Industry Policy Version Number Date Issued Review Date V1 July 2015 13/08/2015 July 2017 Prepared By: Consultation Process:
More informationVersion 1.0. Quality, Performance & Finance. Date Ratified 31 st March 2015 Iain Stewart, Head of Direct Commissioning
Joint working with the pharmaceutical industry Policy (Template based upon DH Best Practice Guidance for Joint Working between the NHS and the Pharmaceutical Industry, February 2008) Version 1.0 Ratified
More informationPOLICY FOR SPONSORSHIP OF ACTIVITIES, JOINT WORKING AND TRAINING AND EDUCATION BY THE PHARMACEUTICAL INDUSTRY WITH
POLICY FOR SPONSORSHIP OF ACTIVITIES, JOINT WORKING AND TRAINING AND EDUCATION BY THE PHARMACEUTICAL INDUSTRY WITH NOTTINGHAMSHIRE CLINICAL COMMISSIONING GROUPS Contents 1. Background... 3 2. Purpose of
More informationNHS Fife WORKING WITH THE PHARMACEUTICAL INDUSTRY AND HEALTHCARE EQUIPMENT SUPPLIERS GUIDANCE FOR NHS STAFF
NHS Fife WORKING WITH THE PHARMACEUTICAL INDUSTRY AND HEALTHCARE EQUIPMENT SUPPLIERS GUIDANCE FOR NHS STAFF This guidance relates to all staff employed by NHS Fife (including staff within the Health &
More informationWORKING WITH THE PHARMACEUTICAL INDUSTRY POLICY Version 1.0
WORKING WITH THE PHARMACEUTICAL INDUSTRY POLICY Version 1.0 1 Standard Operating Procedure St Helens CCG Working with The Pharmaceutical Industry Policy Version 1.0 Implementation Date May 2017 Review
More informationCCG Policy for Working with the Pharmaceutical Industry
CCG Policy for Working with the Pharmaceutical Industry 1. Introduction Medicines are the most frequently and widely used NHS treatment and account for over 12% of NHS expenditure. The Pharmaceutical Industry
More informationWORKING WITH THE PHARMACEUTICAL INDUSTRY
WORKING WITH THE PHARMACEUTICAL INDUSTRY Page 1 of 11 WORKING WITH THE PHARMACEUTICAL INDUSTRY CCG Policy Reference: SuttonCCG/SLCSU/GOV/099 THIS POLICY WILL BE APPROVED BY THE CLINICAL COMMISSIONING GROUP
More informationCommercial Sponsorship and Joint Working with the Pharmaceutical Industry Policy November 2017
Commercial Sponsorship and Joint Working with the Pharmaceutical Industry Policy November 2017 Authorship: Medicines Optimisation Team North of England Commissioning Support Committee Approved: Quality
More informationPHARMACEUTICAL REPRESENTATIVE POLICY NOVEMBER This policy supersedes all previous policies for Medical Representatives
PHARMACEUTICAL REPRESENTATIVE POLICY VEMBER 2017 This policy supersedes all previous policies for Medical Representatives Policy title Pharmaceutical Representative Policy Policy PHA39 reference Policy
More informationCommercial Sponsorship and Joint Working with the Pharmaceutical Industry Policy
Commercial Sponsorship and Joint Working with the Pharmaceutical Industry Policy Ratified Status Approved Final Issued November 2017 Approved By Consultation Governance and Risk Committee CCG Head of Governance
More informationPolicy for Commercial Sponsorship and Joint Working with Pharmaceutical Industry
Item 4.3 Attachment 2 to the Medicines Management Report Policy for Commercial Sponsorship and Joint Working with Pharmaceutical Industry The NHS Walsall CCG Safety Quality and Performance committee SQP
More informationVersion Number Date Issued Review Date V2 September 2017 September Helen Seymour, Senior Medicines Optimisation Pharmacist, NECS
Corporate CO23: Commercial sponsorship and joint working with the pharmaceutical industry Version Number Date Issued Review Date V2 September 2017 September 2019 Prepared By: Reviewed By: Consultation
More informationTHE CODE. Professional standards of conduct, ethics and performance for pharmacists in Northern Ireland. Effective from 1 March 2016
THE CODE Professional standards of conduct, ethics and performance for pharmacists in Northern Ireland Effective from 1 March 2016 PRINCIPLE 1: ALWAYS PUT THE PATIENT FIRST PRINCIPLE 2: PROVIDE A SAFE
More informationPrivate Practice & Fee Paying Work For Medical Staff
Private Practice & Fee Paying Work For Medical Staff Policy: HR69 Policy Descriptor This document sets out standards for Medical Staff employed by the Trust about their conduct in relation to private practice
More informationMEDICINES STANDARD B3: WORKING WITH THE PHARMACEUTICAL INDUSTRY
MEDICINES STANDARD B3: WORKING WITH THE PHARMACEUTICAL INDUSTRY NHS employees and contractors link with the pharmaceutical industry in a number of ways, as a source of information, through the receipt
More informationCorporate/General Finance
Document title: Policy and Guidance for Joint Working with the Pharmaceutical Industry (including rebate schemes) & Commercial Sponsorship of Meetings/Training Events CCG document ref: Author / originator:
More informationTransparency and doctors with competing interests guidance from the BMA
Transparency and doctors with competing interests British Medical Association bma.org.uk British Medical Association Transparency and doctors with competing interests 1 Introduction The need for transparency
More informationPolicy on Sponsorship and Joint Working with the Pharmaceutical Industry and other Commercial Organisations
Policy on Sponsorship and Joint Working with the Pharmaceutical Industry and other Commercial Organisations Page 1 of 23 DOCUMENT CONTROL Policy Title: Purpose: Supersedes: This policy applies to: Circulation:
More informationGuidelines for Pharmacists Relationship with the Pharmaceutical Industry
Guidelines for Pharmacists Relationship with the Pharmaceutical Industry July 2002 These guidelines represent general advice to support and assist pharmacists. It is expected that professional judgement
More informationPOLICY ON JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY. Issued by: Director of Quality, Governance and Patient Safety
POLICY ON JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY Issued by: Director of Quality, Governance and Patient Safety Policy Classification: Corporate Issue No: 001 Page No: 1 of 19 Policy No. POLCP007
More informationBest Practice Guidance for Supplementary Prescribing by Nurses Within the HPSS in Northern Ireland. patient CMP
Best Practice Guidance for Supplementary Prescribing by Nurses Within the HPSS in Northern Ireland patient CMP nurse doctor For further information relating to Nurse Prescribing please contact the Nurse
More informationCODE OF CONDUCT CODE OF ACCOUNTABILITY IN THE NHS
CODE OF CONDUCT CODE OF ACCOUNTABILITY IN THE NHS CODE OF CONDUCT Public Service Values General Principles Openness and Public Responsibilities Public Service Values in Management Public Business and Private
More informationSupporting information for appraisal and revalidation: guidance for pharmaceutical medicine
Supporting information for appraisal and revalidation: guidance for pharmaceutical medicine Based on the Academy of Medical Royal Colleges and Faculties Core for all doctors. General Introduction The purpose
More informationPHARMACIST INDEPENDENT PRESCRIBING MEDICAL PRACTITIONER S HANDBOOK
PHARMACIST INDEPENDENT PRESCRIBING MEDICAL PRACTITIONER S HANDBOOK 0 CONTENTS Course Description Period of Learning in Practice Summary of Competencies Guide to Assessing Competencies Page 2 3 10 14 Course
More informationNHS Lanarkshire Policy for the Availability of Unlicensed Medicines
NHS Lanarkshire Policy for the Availability of Unlicensed Medicines Prepared by: NHS Lanarkshire Chief Pharmacist Endorsed by: Area Drug & Therapeutic Committee Previous Version/Date: Primary Policy Date:
More informationResearch Equipment Grants 2018 Scheme 2018 Guidelines for Applicants Open to members of Translational Cancer Research Centres
Research Equipment Grants 2018 Scheme 2018 Guidelines for Applicants Open to members of Translational Cancer Research Centres Applications close 12 noon 08 March 2018 Contents Definitions 3 Overview 4
More informationCOMIC RELIEF AWARDS THE GRANT TO YOU, SUBJECT TO YOUR COMPLYING WITH THE FOLLOWING CONDITIONS:
Example conditions of grant Below are the standard conditions that we ask grant holders to sign up to when accepting a grant from Comic Relief. These conditions are provided here only as an example; we
More informationSouth East London Interface Prescribing Policy including the NHS and Private Interface Prescribing Guide
South East London Interface Prescribing Policy including the NHS and Private Interface Prescribing Guide 1. Introduction 1.1 This policy has been developed by the South East London Clinical Commissioning
More informationStandards of conduct, ethics and performance
Standards of conduct, ethics and performance September 2010 The General Pharmaceutical Council is the regulator for pharmacists, pharmacy technicians and registered pharmacy premises in England, Scotland
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Interim Process and Methods of the Highly Specialised Technologies Programme
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Principles Interim Process and Methods of the Highly Specialised Technologies Programme 1. Our guidance production processes are based on key principles,
More informationCorporate. Research Governance Policy. Document Control Summary
Corporate Research Governance Policy Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation Date: Review Date:
More information1. daa plc, whose principal address is at Old Central Terminal Building, Dublin Airport, Co Dublin (Funder)
Grant Agreement For office use only Application Number: 1. daa plc, whose principal address is at Old Central Terminal Building, Dublin Airport, Co Dublin (Funder) 2. [NAME OF RECIPIENT], whose principal
More informationCareer Development Fellowships 2018 Guidelines for Applicants. Applications close 12 noon 05 April 2018
Career Development Fellowships 2018 Guidelines for Applicants Applications close 12 noon 05 April 2018 Contents Definitions 3 Overview 4 Career Development Fellowship (CDF) 5 Eligibility 7 Assessment of
More informationand decision making. Initially for a period of three years, then on a rolling contract subject to a notice period of six calendar months.
Post Holder: Contracting Organisation: Job Title: Responsible to: Professionally accountable to: Hours: Duration: Remuneration: Expenses: Status: Dr Philip Anthony Dobson The Designated Body Responsible
More informationContinuing Medical Education (CME) Endorsement Application Guide
Continuing Medical Education (CME) Endorsement pplication Guide Contents bout the College 1 What is CME? 1 Who must do CME? 1 Use of the RNZCGP endorsed event logo 4 Using the online system 4 uestions
More informationABPI Guidance Notes on Joint Working between Pharmaceutical Companies and the NHS and Others for the Benefit of Patients
ABPI Guidance Notes on Joint Working between Pharmaceutical Companies and the NHS and Others for the Benefit of Patients Taking into Consideration the 2008 ABPI Code of Practice for the Pharmaceutical
More informationJOB DESCRIPTION LEAD PRACTICE BASED PHARMACIST. Designated GP Practice in Federation area
JOB DESCRIPTION JOB TITLE: LOCATION: ACCOUNTABLE TO: RESPONSIBLE TO: PROFESSIONALLY RESPONSIBLE TO: LEAD PRACTICE BASED PHARMACIST Designated GP Practice in Federation area Federation Chair Practice Prescribing
More informationSupplier Representative Procedure
Supplier Representative Procedure Version: 7.0 Approval Committee: Date of Approval: 6 October 2015 Ratification Committee (Level 1 documents): Date of Ratification (Level 1 documents): 6 October 2015
More informationNHS ISLE OF WIGHT CLINICAL COMMISSIONING GROUP CLINICAL FUNDING AUTHORISATION POLICY
NHS ISLE OF WIGHT CLINICAL COMMISSIONING GROUP CLINICAL FUNDING AUTHORISATION POLICY AUTHOR/ APPROVAL DETAILS & VERSION CONTROL Author Version Reason for Change Date Status IW CCG Acute V1 New policy Sept
More informationNHS Rotherham CCG Medicines Management Team on behalf of NHS Rotherham CCG. Community Pharmacists in NHS Rotherham CCG
SERVICE LEVEL AGREEMENT TO ENABLE COMMUNITY PHARMACISTS IN NHS ROTHERHAM CLINICAL COMISSIONING GROUP TO SUPPLY TREATMENT AND ADVICE FOR MINOR AILMENTS PREPARED BY: NHS Rotherham CCG Medicines Management
More informationJOB DESCRIPTION. 2. To participate in the delivery of medicines administration depending on local need and priorities.
JOB DESCRIPTION JOB TITLE: Clinical Pharmacy Technician PAY BAND: 5 DEPARTMENT/DIVISION: BASED AT: REPORTS TO: PHARMACY/A5 University Hospitals Birmingham Pharmacy Support Manager PROFESSIONALLY RESPONSIBLE
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust. Access to Drugs Policy
The Newcastle upon Tyne Hospitals NHS Foundation Trust Access to Drugs Policy Version No.: 3.0 Effective From: 25 January 2016 Expiry Date: 25 January 2019 Date Ratified: 4 November 2015 Ratified By: Medicines
More informationDear Colleague. November 2013
NHS Circular: PCA (P) (2013) 29 ehealth, Finance & Pharmaceutical Directorate Pharmacy & Medicines Division Dear Colleague ADDITIONAL PHARMACEUTICAL SERVICES INTRODUCTION OF GLUTEN FREE FOOD SERVICE TIMETABLE,
More informationDaiichi Sankyo Group Global Marketing Code of Conduct
Daiichi Sankyo Group Global Marketing Code of Conduct TABLE OF CONTENTS 1. PURPOSE... 3 2. SCOPE... 3 3. TERMS... 3 4. COMPLIANCE WITH LOCAL LAWS, REGULATIONS AND INDUSTRY CODES... 4 5. BASIS OF INTERACTIONS...
More informationStandards for Registered Pharmacies
Council meeting 13 September 2012 Public business Standards for Registered Pharmacies Purpose This paper seeks the Council s approval of the standards for registered pharmacies. The Council is asked to
More informationSupporting information for appraisal and revalidation: guidance for psychiatry
Supporting information for appraisal and revalidation: guidance for psychiatry Based on the Academy of Medical Royal Colleges and Faculties Core for all doctors. General Introduction The purpose of revalidation
More informationPolicy on the Commissioning of NHS Continuing Healthcare for Adults: Assuring Equity, Choice and Value for Money
Policy Statement No. Salford Clinical Commissioning Group Policy on the Commissioning of NHS Continuing Healthcare for Adults: Assuring Equity, Choice and Value for Money Lead for development & revisions
More informationTerms and Conditions of studentship funding
Terms and Conditions of studentship funding Any offer of PhD funding from Brain Research UK ( the Charity ) is subject to the following Terms and Conditions. By accepting the award, the Host Institute
More informationAccreditation of an Education and Training Programme to prepare Pharmacist Independent Prescribers, Sheffield Hallam University
Accreditation of an Education and Training Programme to prepare Pharmacist Independent Prescribers, Sheffield Hallam University Report of an accreditation event, 11 March 2015 Introduction The General
More informationProfessional Practices Policy (P3)
Novartis Global Policy Professional Practices Policy (P3) Novartis Global Policy March 1st, 2018 Version GIC 102.V1.EN NOVARTIS GLOBAL POLICY 2 Contents 1 Introduction... 3 2 Principles... 4 3 Policy...
More informationCode of Ethics and Professional Conduct for NAMA Professional Members
Code of Ethics and Professional Conduct for NAMA Professional Members 1. Introduction All patients are entitled to receive high standards of practice and conduct from their Ayurvedic professionals. Essential
More informationRESEARCH GOVERNANCE POLICY
RESEARCH GOVERNANCE POLICY DOCUMENT CONTROL: Version: V6 Ratified by: Performance and Assurance Group Date ratified: 12 November 2015 Name of originator/author: Assistant Director of Research Name of responsible
More informationSupporting information for appraisal and revalidation: guidance for Supporting information for appraisal and revalidation: guidance for ophthalmology
FOREWORD As part of revalidation, doctors will need to collect and bring to their appraisal six types of supporting information to show how they are keeping up to date and fit to practise. The GMC has
More informationRegional Medicines Optimisation Committees
Regional Medicines Optimisation Committees Operating Model First Edition, April 2017 NHS England INFORMATION READER BOX Directorate Medical Commissioning Operations Patients and Information Nursing Trans.
More informationContribute to society, and. Act as stewards of their professions. As a pharmacist or as a pharmacy technician, I must:
Code of Ethics Preamble Pharmacists and pharmacy technicians play pivotal roles in the continuum of health care provided to patients. The responsibility that comes with being an essential health resource
More informationThe use of lay visitors in the approval and monitoring of education and training programmes
Education and Training Committee, 12 September 2013 The use of lay visitors in the approval and monitoring of education and training programmes Executive summary and recommendations Introduction This paper
More informationPerformance and Quality Committee
Title: NHS Continuing Health Care Choice Policy (addendum to Cornwall Wide Patient Choice, Equity and Fair Access Policy) Developed by: Document type: Policy library: NHS Kernow Policy Policies Sub Section:
More informationGPhC response to the Rebalancing Medicines Legislation and Pharmacy Regulation: draft Orders under section 60 of the Health Act 1999 consultation
GPhC response to the Rebalancing Medicines Legislation and Pharmacy Regulation: draft Orders under section 60 of the Health Act 1999 consultation Background The General Pharmaceutical Council (GPhC) is
More informationStandards conduct, accountability
Standards of conduct, accountability and openness Standards of conduct, accountability and openness Throughout this document: members refers to all members of a board the Chair, the non-executives, the
More informationSupporting information for appraisal and revalidation: guidance for Occupational Medicine, June 2014
Supporting information for appraisal and revalidation: guidance for Occupational Medicine, June 2014 Based on the Academy of Medical Royal Colleges and Faculties Core for all doctors. General Introduction
More informationSupporting information for appraisal and revalidation: guidance for Occupational Medicine, April 2013
Supporting information for appraisal and revalidation: guidance for Occupational Medicine, April 2013 Based on the Academy of Medical Royal Colleges and Faculties Core for all doctors. General Introduction
More informationInformation shared between healthcare providers when a patient moves between sectors is often incomplete and not shared in timely enough fashion.
THE DISCHARGE MEDICINES REVIEW SERVICE Introduction During a stay in hospital a patient s medicines may be changed. Studies show that many patients may experience an error or problem with their medicines
More informationMedicines Management Policy
Medicines Management Policy Name of Policy: Purpose of Policy: Directorate responsible for Policy Name & Title of Author: Medicines Management Policy The Southern HSC Trust recognises that almost all patients
More informationCODE OF CONDUCT POLICY
CODE OF CONDUCT POLICY Mandatory Quality Area 4 PURPOSE This policy will provide guidelines to: establish a standard of behaviour for the Approved Provider (if an individual), Nominated Supervisor, Certified
More informationabcdefghijklmnopqrstu
Healthcare Policy and Strategy Directorate Quality Division Dear Colleague INTRODUCTION AND AVAILABILITY OF NEWLY LICENSED MEDICINES IN THE NHS IN SCOTLAND Dear Colleague This guidance sets out the policy
More informationMedicines Management Strategy
Medicines Management Strategy 2012 2014 Directorate responsible for the strategy: Medical and Governance Directorate Staff group to whom it applies: All clinical staff and Trust managers Issue date: 30/6/12
More informationJOB DESCRIPTION. Psychiatrist REPORTING TO: CLINICAL DIRECTOR - FOR ALL CLINICAL MATTERS SERVICE MANAGER FOR ALL ADMIN MATTERS DATE: APRIL 2017
JOB DESCRIPTION Psychiatrist SECTION ONE DESIGNATION: CONSULTANT PSYCHIATRIST MEDICAL OFFICER PSYCHIATRY NATURE OF APPOINTMENT: FULL TIME/10/10THS FTE LOCATION: WEEKLY TIMETABLE: INDICATIVE ONLY REPORTING
More informationHigh level guidance to support a shared view of quality in general practice
Regulation of General Practice Programme Board High level guidance to support a shared view of quality in general practice March 2018 Publications Gateway Reference: 07811 This document was produced with
More informationStandards of Practice for Optometrists and Dispensing Opticians
Standards of Practice for Optometrists and Dispensing Opticians effective from April 2016 Standards of Practice for Optometrists and Dispensing Opticians Standards of Practice Our Standards of Practice
More informationApprenticeship Standard for Nursing Associate at Level 5. Assessment Plan
Apprenticeship Standard for Nursing Associate at Level 5 Assessment Plan Summary of Assessment On completion of this apprenticeship, the individual will be a competent and job-ready Nursing Associate.
More informationGUIDANCE ON SUPPORTING INFORMATION FOR REVALIDATION FOR SURGERY
ON SUPPORTING INFORMATION FOR REVALIDATION FOR SURGERY Based on the Academy of Medical Royal Colleges and Faculties Core Guidance for all doctors GENERAL INTRODUCTION JUNE 2012 The purpose of revalidation
More informationNON-MEDICAL PRESCRIBING POLICY
NON-MEDICAL PRESCRIBING POLICY To be read in conjunction with the Medicines Policy, Controlled Drug Policy and the FP10 Prescribing Forms Policy Version: 5 Date of issue: August 2017 Review date: August
More informationContinuing Healthcare Policy
Continuing Healthcare Policy 1 SUMMARY This policy describes the way in which Haringey Clinical Commissioning Group (HCCG) will make provision for the care of people who have been assessed as eligible
More informationabcdefghijklmnopqrstu
Directorate for Chief Medical Officer, Public Health and Sport Sir Harry Burns, MPH FRCS (Glas) FRCP(Ed) FFPH Health and Social Care Directorate Pharmacy and Medicines Division Professor Bill Scott, MSc,
More informationJOB DESCRIPTION. Consultant Physician, sub-specialty in Gastroenterology REPORTING TO: HEAD OF DEPARTMENT - FOR ALL CLINICAL MATTERS
JOB DESCRIPTION Consultant Physician, sub-specialty in Gastroenterology SECTION ONE DESIGNATION: CONSULTANT PHYSICIAN, SUB-SPECIALTY GASTROENTEROLOGY NATURE OF APPOINTMENT: FULL OR PART TIME REPORTING
More informationINSTITUTION OF ENGINEERS RWANDA
INSTITUTION OF ENGINEERS RWANDA CODE OF PROFESSIONAL ETHICS FOR IER 1 P a g e Forward Dear IER members, Engineering is a profession requiring a high standard of scientific education together with specialized
More informationGeneric Job Description Consultant Pharmacist. Job Purpose
Generic Job Description Consultant Pharmacist Grade: Based at: 8b-d Operating sites as required Accountable to: Head of Pharmacy/Clinical Director of Pharmacy/ Divisional director or equivalent Managed
More informationCCG authorisation: the role of medicines management
May 2012 The NHS medicines bill for 2010 was 12.9 billion, of which secondary care costs accounted for 32%. Prescribing inflation in 2010 ran at 4.8% and it is estimated that around 14% of total CCG budgets
More informationCasual Worker Agreement Form. This agreement is between: Casual Worker (name): The Royal Liverpool & Broadgreen University Hospitals NHS Trust
Casual Worker Agreement Form This agreement is between: Casual Worker (name): Organisation: The Royal Liverpool & Broadgreen University Hospitals NHS Trust Terms of Agreement START DATE: JOB TITLE: Registered/Unregistered
More informationJOB DESCRIPTION. Specialist Practitioner of Transfusion for Shrewsbury, Telford and surrounding community hospitals. Grade:- Band 7 Line Manager:-
JOB DESCRIPTION Job Title:- Specialist Practitioner of for Shrewsbury, Telford and surrounding community hospitals. Grade:- Band 7 Line Manager:- Associate Director of Patient Safety Professionally Accountability
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust. Introduction and Development of New Clinical Interventional Procedures
The Newcastle upon Tyne Hospitals NHS Foundation Trust Introduction and Development of New Clinical Interventional Procedures Version No.: 2.1 Effective From: 27 November 2017 Expiry Date: 7 January 2019
More informationVersion Number: 004 Controlled Document Sponsor: Controlled Document Lead:
Chief Investigators and Principal Investigators in Research Policy CONTROLLED DOCUMENT CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Policy Governance To set out the responsibilities of
More informationJOB DESCRIPTION. 1. General Information. GRADE: Band hours per week ACCOUNTABLE TO:
1. General Information JOB DESCRIPTION JOB TITLE: Senior Staff Nurse/ ODP GRADE: Band 6 HOURS: RESPONSIBLE TO: ACCOUNTABLE TO: 37.5 hours per week Sister/Charge Nurse Matron Organisational Values: Our
More informationThe code: Standards of conduct, performance and ethics for nurses and midwives
The code: Standards of conduct, performance and ethics for nurses and midwives We are the nursing and midwifery regulator for England, Wales, Scotland, Northern Ireland and the Islands. We exist to safeguard
More informationASSOCIATION FOR ACCESSIBLE MEDICINES Code of Business Ethics. March 2018
ASSOCIATION FOR ACCESSIBLE MEDICINES Code of Business Ethics March 2018 Introduction Improving patient access to affordable medicines is a core value of companies that develop and manufacture generic and
More informationNorthumbria Healthcare NHS Foundation Trust. Charitable Funds. Staff Lottery Scheme Procedure
Northumbria Healthcare NHS Foundation Trust Charitable Funds Staff Lottery Scheme Procedure Version 1 Name of Policy Author Alison Nell Date Issued 1 st March 2017 Review Date 1 st March 2018 Target Audience
More informationNICE Charter Who we are and what we do
NICE Charter 2017 Who we are and what we do 1. The National Institute for Health and Care Excellence (NICE) is the independent organisation responsible for providing evidence-based guidance on health and
More informationThe code. Standards of conduct, performance and ethics for nurses and midwives
The code Standards of conduct, performance and ethics for nurses and midwives 1 We are the nursing and midwifery regulator for England, Wales, Scotland, Northern Ireland and the Islands. We exist to safeguard
More informationFORTH VALLEY CLINICAL AND CARE GOVERNANCE FRAMEWORK
HEALTH AND SOCIAL CARE INTEGRATION: FORTH VALLEY CLINICAL AND CARE GOVERNANCE FRAMEWORK The Scottish Government, National Health and Wellbeing Outcomes: A framework for improving the planning and delivery
More informationPharmacist (Palliative Care) December 2014 Page 1
Job Profile Job Title: Department: Main Location: Hospice Palliative Care Pharmacist 7 NHS (8SRC) Less than full time(0.8) Full time equivalent around 36,300 Head of Clinical Services 1. Main Purpose of
More informationThe Mexico City Principles For Voluntary Codes of Business Ethics in the Biopharmaceutical Sector
The Mexico City Principles For Voluntary Codes of Business Ethics in the Biopharmaceutical Sector E thical interactions help ensure that medical decisions are made in the best interests of patients. For
More informationGUIDANCE NOTES FOR THE EMPLOYMENT OF SENIOR ACADEMIC GPs (ENGLAND) August 2005
GUIDANCE NOTES FOR THE EMPLOYMENT OF SENIOR ACADEMIC GPs (ENGLAND) August 2005 Guidance Notes for the Employment of Senior Academic GPs (England) Preamble i) A senior academic GP is defined as a clinical
More informationEthical framework for priority setting and resource allocation
Ethical framework for priority setting and resource allocation UNIQUE REF NUMBER: CD/XX/083/V2.0 DOCUMENT STATUS: Approved - Commissioning Development Committee 16 August 2017 DATE ISSUED: August 2017
More informationNHS WOLVERHAMPTON CLINICAL COMMISSIONING GROUP CONSTITUTION
NHS WOLVERHAMPTON CLINICAL COMMISSIONING GROUP CONSTITUTION Version: [78] NHS England Effective Date: 1 December 2015 April 2017 CONTENTS Part Description Page Foreword 1 1 Introduction and Commencement
More informationabcdefghijklmnopqrstu
Director-General Health and Chief Executive NHS Scotland Dr Kevin Woods abcdefghijklmnopqrstu T: 0131-244 2410 F: 0131-244 2162 E: dghealth@scotland.gsi.gov.uk CEL 4 (2010) Dear Colleague INFORMING, ENGAGING
More informationCode of professional conduct
& NURSING MIDWIFERY COUNCIL Code of professional conduct Protecting the public through professional standards RF - NMC 317-032-001 & NURSING MIDWIFERY COUNCIL Code of professional conduct Protecting the
More information